Hansa Biopharma AB (HNSA) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.253x

Based on the latest financial reports, Hansa Biopharma AB (HNSA) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-111.70 Million ≈ $-12.02 Million USD) by net assets (Skr-441.06 Million ≈ $-47.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hansa Biopharma AB market capitalisation for the company's overall valuation and market capitalisation.

Hansa Biopharma AB - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Hansa Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hansa Biopharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hansa Biopharma AB ranked by their cash flow conversion efficiency. See how well can Hansa Biopharma AB service its debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Shenzhen Zqgame SHE:300052	0.010x
Styrenix Performance Materials Limited NSE:STYRENIX	-0.052x
Magnetic Resources NL AU:MAU	-0.125x
Chengdu Rainbow Appliance Gr SHE:003023	-0.053x
Duratec Ltd AU:DUR	0.215x
Novavest Real Estate Ag SW:NREN	0.031x
Yung Chi Paint & Varnish Mfg Co Ltd TW:1726	-0.003x
HOMAG Group AG F:HG1	0.056x

Annual Cash Flow Conversion Efficiency for Hansa Biopharma AB (2008–2024)

The table below shows the annual cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024. View Hansa Biopharma AB share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr-589.83 Million ≈ $-63.48 Million	Skr-674.88 Million ≈ $-72.63 Million	1.144x	-74.58%
2023-12-31	Skr-167.88 Million ≈ $-18.07 Million	Skr-755.65 Million ≈ $-81.32 Million	4.501x	+639.82%
2022-12-31	Skr602.91 Million ≈ $64.88 Million	Skr-502.73 Million ≈ $-54.10 Million	-0.834x	-31.28%
2021-12-31	Skr757.57 Million ≈ $81.53 Million	Skr-481.17 Million ≈ $-51.78 Million	-0.635x	-171.79%
2020-12-31	Skr1.24 Billion ≈ $133.67 Million	Skr-290.27 Million ≈ $-31.24 Million	-0.234x	+60.71%
2019-12-31	Skr562.82 Million ≈ $60.57 Million	Skr-334.77 Million ≈ $-36.03 Million	-0.595x	-150.04%
2018-12-31	Skr859.88 Million ≈ $92.54 Million	Skr-204.56 Million ≈ $-22.01 Million	-0.238x	+0.05%
2017-12-31	Skr630.66 Million ≈ $67.87 Million	Skr-150.10 Million ≈ $-16.15 Million	-0.238x	+28.60%
2016-12-31	Skr283.69 Million ≈ $30.53 Million	Skr-94.56 Million ≈ $-10.18 Million	-0.333x	-21.99%
2015-12-31	Skr211.53 Million ≈ $22.76 Million	Skr-57.80 Million ≈ $-6.22 Million	-0.273x	+42.39%
2014-12-31	Skr49.80 Million ≈ $5.36 Million	Skr-23.62 Million ≈ $-2.54 Million	-0.474x	-45.75%
2013-12-31	Skr45.68 Million ≈ $4.92 Million	Skr-14.87 Million ≈ $-1.60 Million	-0.325x	+0.26%
2012-12-31	Skr63.24 Million ≈ $6.81 Million	Skr-20.63 Million ≈ $-2.22 Million	-0.326x	+58.28%
2011-12-31	Skr34.71 Million ≈ $3.74 Million	Skr-27.14 Million ≈ $-2.92 Million	-0.782x	-39.01%
2010-12-31	Skr32.17 Million ≈ $3.46 Million	Skr-18.09 Million ≈ $-1.95 Million	-0.563x	-1.64%
2009-12-31	Skr24.92 Million ≈ $2.68 Million	Skr-13.79 Million ≈ $-1.48 Million	-0.553x	-44.73%
2008-12-31	Skr40.73 Million ≈ $4.38 Million	Skr-15.58 Million ≈ $-1.68 Million	-0.382x	--

About Hansa Biopharma AB

ST:HNSA Sweden Biotechnology

Market Cap

$393.01 Million

Skr3.65 Billion SEK

Market Cap Rank

#13626 Global

#217 in Sweden

Share Price

Skr36.62

Change (1 day)

-4.24%

52-Week Range

Skr24.88 - Skr46.68

All Time High

Skr348.00